SCD
LMP Capital And Income Closed Fund
Mentions (24Hr)
0.00% Today
Reddit Posts
$ICU - SeaStar Medical Names David Green as Finance Chief, Mentions Commercial Launch of SCD-PED LATER THIS QUARTER (IMPLYING FDA APPROVAL)
$ICU - SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
CRSP Stock Surges after winning the first ever gene editing approval
ICU - SeaStar Medical, shirt squeeze incoming
SeaStar Medical Holdings (ICU) insane potential.
SeaStar Medical Holdings (ICU) insane potential.
$ICU 2.6 mill FLOAT deSPAC IMO we get back to $4's
$icu 2.6 mill FLOAT deSPAC IMO we get back to $4's
Medical Cannibas - $BGXX, My Why Buy
Amesite: Ed-Tech for Enterprises is a great SaaS play
SobrSafe Inc. - Addressing the $200B per year problem in the workplace
Champion Gaming: The Sports Betting Pick and Shovel Play
Troika Media: Swing trade of the year!
Global Blood Therapeutics (GBT) potential upside of ~172% over the coming months
$QIPT: Lots of ways to win - Part II The Catalysts
Mentions
Shockingly accurate especially based on predicted yields so far for scandium and other rare earth metals. SCD even with current outstanding shares could see a market value over 1b IF it ends up a fully operational mining company, not to mention the added value of patents. This translates to a fair market value of about 2.77 cad.
SCD.V SCDCF My best long term play atm. Can’t wait til it pops
I actually agree with you on SCD.V. Bought some last week and it was up 21% yesterday. With all the rare earth increases I like this one for future gains.
SCD.V SCDCF super under the radar play for the next while
Kk sounds good, please respond when you have had a chance to look. I didn't notice any gold with SCD. I did see the refinement patents and over 100 square km of land they have in QC. But clearly I missed gold mining. Will have to take another look today
Have you looked into the potential of SCD on the tsx? Scandium Canada. Patents and land, looks way undervalued with a huge potential upside, but I'd appreciate another perspective
SCD.V minerals play looking like a good setup
So interesting, I personally know a few people with SCD so I’ll be looking into this one further for sure. There’s not much out there by way of curative treatments for SCD.
Hoping SCD.V is the next metals play
I held SCD before so i was thinking of that. Gonna chk out the other though and see what im poss missing there. Thanks!
A couple of higher yielding managed ETFs I like are SCD and JRI. Maybe worth a look for you.
That’s a fair take and agree that the PED program does provide a floor, but I still view SeaStar as mostly binary: * **HDE limits PED adoption.** Each hospital needs separate IRB approval, which takes months. Even 1.5 years post-approval, adoption is still limited. Without strong adult data, full FDA approval for QUELIMMUNE is far from certain. * **Adult trial failure could hurt credibility.** A weak NEUTRALIZE-AKI outcome may raise doubts about the SCD platform overall, slowing FDA progress and payer confidence for both adult and pediatric use. * **Acquisition risk.** If the tech truly disrupts, big pharma could step in , but possibly to shelve it, not grow it, especially if it threatens existing revenue. * **Dilution risk remains.** Even with some PED growth, more funding is likely needed before adult revenues. One offering at current prices could dilute shareholders another 10 to 20%. So while the downside isn’t zero, I still think the real upside. Institutional interest will make the difference, depends on the adult trial. I'm confident it will not failt, but it will still be the most important event for Seastar so far.
I hear you. Cash via revenue would be great ANY DAY now. Been following this stocks since the pediatric SCD FDA approval. Just feeling like they sort of “owe” us an update on when the company is going to make revenue. It’s not a big ask.
ARA has nearly grown 100% for me. SCD and SCY are looking well. FL and [MILI.CN](http://MILI.CN) also up. If I wasn't already at my target allocation for critical minerals...
I am interested in their LNP heme editing approach for SCD/Beta-Thal. Its the clear winner for the disease space because it does not require the harmful conditioning regime that Casgevy does. On the other hand they are down to $200M in cash and many other companies are pursuing the same approach. I think it keeps squeezing with the rest of the biotech sector.
I've mostly bet on small cap and often pre-profit companies hoping for eventual high returns. Especially bullish on Scandium Canada (SCD.TO), and I'm up a high double digit on Aclara Resources (ARA.TO). Also in MILI Military Metals and FV Frontier Lithium.
$ICU (SeaStar Medical), through the AREVA Institute, announced a $2M DoD grant to advance their breakthrough research on severe burn treatment. [AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research](https://www.globenewswire.com/news-release/2025/06/11/3097525/0/en/AREVA-Institute-and-SeaStar-Medical-Announce-DoD-Award-of-Prestigious-Military-Grant-to-AREVA-Institute-to-Evaluate-SeaStar-Medical-s-SCD-Therapy-to-Advance-Breakthrough-Burn-and-S.html)
This company has no idea what they are doing with aramchol. It’s been NASH, AIDS, gallstones, oncology. Just give up already. It looks like SCD1 isn’t a great target. Now they’re reformulating semaglutide for sublingual? Meanwhile, oral semaglutide literally exists. I don’t see the point. Also, they’re based out of Israel. I’m done investing in and working with companies out of Florida and Israel. Nothing but grifters. CEO’s total comp was 1.7M for 2024. That’s a pretty large amount for a company with a $3M market cap.
Underlying robotics, defence and a lot of the other advanced sectors - My bet is on Rare Earth minerals developed in the west, especially Canada (for me). Currently I'm invested in Scandium Canada (SCD.TO) which I'm VERY bullish about because of their progress in alloy creation and ongoing improvements. They are nearly exiting pre-viability into actual production, which would be big for me since I have a significant holding. I'm also in Frontier Lithium, Aclara mining for magnet production, and Military Metals (for antimony). Although these are all high risk except perhaps Frontier and Aclara who'd be Medium (at best), I'm hoping that large scale societal investments will come within the next 10 years as governments continue to realize that full dependence on China for these vital supply chains is unsustainable. Clear energy, electric vehicles, defence, drones, space... In the end, all of them rely on mineral production. So, that's why bet, and why.
To all NVDA put sellers, call buyers and shareholders >Sudden cardiac death (SCD), a leading cause of mortality worldwide, is estimated to affect 4-5 million people annually. It's responsible for more than half of all cardiac deaths and up to 20% of overall deaths. SCD can occur in people of all ages, even those who appear healthy. What if Jensen has a heart attack during this 3-day weekend? At what price you think the stock will open on Tuesday?
GLMD Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Per Grok 1. For BLRX, at $2.96, a surge to $26 (the H.C. Wainwright target) would require relatively little volume if the float is, say, 1.5 million ADSs. For example, 500,000 shares traded (a third of the float) could trigger a squeeze, pushing the price up fast. Retail investors chasing quick gains might find this appealing, especially after the March 31, 2025, press conference highlighted pipeline momentum and cost efficiencies. 2. Short Squeeze Opportunities: Low-float stocks are prime candidates for short squeezes if short interest builds. As of early 2025, BLRX’s short interest was around 5.61% of its float (per MarketBeat data), or roughly 84,000-112,000 ADSs if the float is 1.5-2 million. If positive news—like a new in-licensing deal or SCD trial data—sparks buying, short sellers covering could amplify the rally. Retail investors who got in early could see outsized returns, as seen in past low-float biotech runs (e.g., Cassava Sciences in 2021). 3. Amplified Impact of Catalysts: The press conference emphasized upcoming catalysts: in-licensing new assets in 2025, CheMo4METPANC interim results (2026-2027), and SCD trial progress. With a low float, these events could disproportionately move the stock. For instance, a $10 million milestone payment from Ayrmid (part of the $87 million potential) could double the current $11.45 million market cap, and limited shares mean the price reacts sharply. Retail investors might see this as a chance to ride speculative waves. 4. Retail-Driven Momentum: Low-float stocks often attract retail trader communities (e.g., on X or StockTwits), where coordinated buying can gain traction. BLRX’s small size and recent strategic pivot to "BioLineRx 2.0" could make it a buzzworthy pick, especially if X chatter picks up post-conference. This social momentum can draw in risk-tolerant investors seeking a "lottery ticket" play. ### Enticing Aspects and Caveats - Upside Potential: A move from $2.96 to $26 offers a 778% return, far exceeding typical market gains. The low float magnifies this possibility, making it a tantalizing bet for retail investors with small positions (e.g., $1,000 could become $8,780). - Volatility as Opportunity: The stock’s 52-week range ($0.14-$3.24) shows it can swing hard. Retail investors comfortable with day-trading or holding through dips might see this as a feature, not a bug. - Risks: The flip side is steep declines if catalysts disappoint. A low float cuts both ways—selling pressure can crash the price just as fast. Plus, BLRX’s ongoing losses (-$9.2 million in 2024) and reliance on milestones add fundamental risk. ### Conclusion BLRX’s low float is inferred from its post-split ADS count and typical biotech ownership patterns, likely landing it in the 1-2 million share range. For retail investors, the allure lies in potential rapid gains, short squeeze setups, and catalyst-driven spikes—benefits heightened by the float’s scarcity. It’s enticing for those who thrive on volatility and biotech speculation, but the high risk of wipeout demands caution. If the strategy shift and pipeline deliver, the low float could be a rocket booster; if not, it’s a rollercoaster with no brakes.
The reason for insane costs of simple things like screws is due to the government requirements. It’s not an off the shelf screw from Home Depot. Most parts are given a “Specification Control Document” (SCD) that has requirements for environmental testing, lot controls, etc. All the extra testing and traceability is what adds to the cost.
CRSPR Therapeutics SCD cure costs about $2m. There is a market for curing diseases, and a profitable one and they're just getting started.
Gene therapies are priced in millions of dollars, so even for rare genetic diseases such as HAE, AATD, SCD (diseases currently being targeted by gene editing companies) there is the potential to make billions in revenue. Also, the patient population will still grow as new humans are born with the disease since these therapeutic edits are somatic and not heritable. The first CRISPR based drug (Casgevy) was approved at the end of last year for sickle cell and is priced at $2.2M, and the manufacturer (Vertex) anticipates they can dose 35k patients across US and Europe.
A lot of people game the system [https://www.militarytimes.com/veterans/2023/09/25/va-officials-sound-alarm-on-uptick-in-veterans-benefits-scams/](https://www.militarytimes.com/veterans/2023/09/25/va-officials-sound-alarm-on-uptick-in-veterans-benefits-scams/) [https://www.va.gov/vetdata/docs/QuickFacts/SCD\_trends\_FINAL\_2018.PDF](https://www.va.gov/vetdata/docs/QuickFacts/SCD_trends_FINAL_2018.PDF)
Crsp - first to market treating SCD, 2B in cash for runway, opening up in markets all over the world, UK, Canada, Saudi Arabia recently. It's a miracle cure that is real and worth billions. Current Mcap is ridiculously small at 4b.
The ambulance chaser lawsuits are pertaining to an event that happened in May of 2023 when the FDA turned down their HDE application for the pediatric SCD. [SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device](https://investors.seastarmedical.com/news/news-details/2023/SeaStar-Medical-Provides-Regulatory-Update-Related-to-its-HDE-Application-for-Pediatric-Selective-Cytopheretic-Device/default.aspx) The FDA indicated that the application is not approvable in its current form but outlined specific guidance as to how the application may be amended and resubmitted successfully-- The FDA later approved the resubmission. Please read the risk factors located in the company's 10-K, you will understand that there is no ground for litigation here. The lawsuits have no validity whatsoever. Ambulance chaser law firms that attack everyone hoping something sticks. Just look at their websites.
CRSP They just cured SCD and have more in the pipeline, future of medicine. https://www.bbc.co.uk/news/articles/c4gzldll44lo The stock is extremely undervalue right now. I'm all in.
Not to be a sarcastic ass once again. But this is Dot Com 2.0. If you are DCA into the market, it maybe time to start a position in either $RSP, $SCD, and/or $GLD if you haven't already. Market corrections teach you the need to diversify. Everyone looks like a fricking genius in a bull market. Those that diversify and stay in during bear markets win the day. It's easier to stay in the market when everything you own isn't blood Red every day, week, month, & year in market corrections. That's why hedges like Gold are needed in a port. Gold helped me stay in the market after dot com and 2008 GFC.
I think it has a decent shot as a looong hold, but not really expecting a big short term move without a catalyst. I took profits for now but I'm still watching it, maybe play the run up to adult approval and/or their first earnings call with SCD revenue.
Hear me out… ICU. Do your own DD, but if you have a fundamental knowledge of the human anatomy, you’ll see what a big deal their “SCD” is. If you don’t look at it in-depth, don’t cry later. Save this for 1 year.
You can read up on side effects of Casgevy vs the vector based treatment for SCD that was approved at the same time. I would say it speaks volumes.
Why do you think it's not priced in, and why would their SCD device be a major innovation? I'm not too deep into the medical field so any info is appreciated.
Crsp is a promising one considering they hold many patents on their new and emerging gene therapy, Crispr- Cas9. This technology is about 10 years old now but it has been incredibly impactful and revolutionary to the scientific community. Their new product, in collaboration with Vertex Pharmaceuticals 60/40, Casgevy, just got approved by the European Commission to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). These are diseases with currently no cure until now (provided it shows good results in their limited release to 8000 patients) they plan to do the same with autoimmune diseases such as lupus which currently also has no cure. There are still results that need to be seen but it’s definitely going in the right direction and looks promising. As such with biotech, there is still a lot of risk in it still but with a current market cap of 7B, positive earnings, and alot of cash in hand to continue their studies, I can definitely say I like this stock! Will be holding for awhile and adding on dips. I am not a financial advisor!!
Any thoughts on the ICU sell-off? I don't think it's merely a sell the news event. IMO, a significant factor in why it fell so hard is the fact that it's a HDE approval rather than a full FDA approval. I think people did DD pertaining to SCD-PED upon receiving the news and saw that the market for this device is extremely small.
Yes. This is only the start for ICU I think. low $0.80s a good start for anyone new as well. Big accumulation here and I expect buyout ultimately. A lot to like about this company and most importantly their SCD device.
I'm in with 45,000 shares. Was tough that the de-SPAC transaction really happened at the worst time (Fall 2022) and just allowed for bleeding/shorting. On the bright side, their SCD-PED looks like it's on the verge of FDA approval; which means SeaStar will officially begin generating revenue. Seems like this would be the time to average down if you are in this from 20223 or early 2023.
Junk stock being pumped. Interesting. What I have read and researched is that $ICU SeaStar Medical's SCD is an innovative disruptive technology that is clinically showing incredible efficacy that is statistically significant in almost every way imaginable. In a high percentage of AKI cases to date, SCD has not only stopped inflammation, but it has also reversed kidney damage for patients with renal failure. It has been so effective, it has actually in some cases completely eliminated dialysis dependency. It is saving lives and drastically improving patient outcomes. It is also indication agnostic, so the potential and scope of the application is vast. It has also shown effective in helping the body bounce back to a stable level of vitals and strength, so they can then have life-saving organ transplants surgery or LVAD implants. So as convincing an argument as you make, I respectfully disagree based on the science, clinical date to date and scope of indications. My personal thesis is that this breakthrough discovery and resulting SCD device will change the landscape of patient care relative to patient's fighting inflammation and cytokine storms. It will be adopted by such a high percentage of hospitals, that it will universally be recognized as the new standard of care for patients fighting inflammation and cytokine storms
I hear you on this. Fair argument. I will say this, I have been surprised by some of their moves, but I have seen in time that it all lends itself to very strong execution in my opinion. So I am personally very bullish on the SeaStar leadership team. I think you will see a 2 months time that they have played this beautifully and set the company, the shareholders, and their SCD technology up for great success.
"SeaStar Medical expects to receive U.S. Food & Drug Administration (FDA) approval for its SCD Pediatric (SCD-PED) under a Humanitarian Device Exemption (HDE) for use in children weighing 10 kilograms or more with AKI and sepsis or a septic condition requiring continuous CKRT anytime within the next 30 to 45 days and to commence commercialization of the SCD-PED in Q1 2024." - December 28, 2023 Source: [https://investors.seastarmedical.com/news/news-details/2023/SeaStar-Medical-Updates-Subject-Enrollment-in-its-Pivotal-Trial-with-the-Selective-Cytopheretic-Device-in-Adults-with-Acute-Kidney-Injury/default.aspx](https://investors.seastarmedical.com/news/news-details/2023/seastar-medical-updates-subject-enrollment-in-its-pivotal-trial-with-the-selective-cytopheretic-device-in-adults-with-acute-kidney-injury/default.aspx)
Why does that seem... high? If SCD-ADULT receivs FDA approval next year (2025), they now have a 200,000 person market annually for their first indication. If treatment costs $5000 (I have no idea how much it costs but that sounds like a fair number), that's $1b revenue. And that is from a single indication. $1b annual revenue would put us at what marketcap? Idk. $1b marketcap puts us at like $20/share. Seems pretty low to me by the END of 2027. But... i dunno.
Guys, the stock has only dipped down to where it was LAST WEEK. It's been doing nothing but going up for a while, and at the first dip, people wanna bail? It went down for a reason. The SCD is still pending FDA approval, it's still going to be in a lot of hospitals. The company isn't tanking, the price is still up 44% compared to a month ago. Stocks are not always easy money, just stay calm guys, it will recover soon.
Not worried in the slightest. Shelf offering thats been in their financials for a year. Funding was necessary to expedite SCD-ADULT trials. After FDA approval, no need for reverse split or additional dilution. Clearer path ahead. Also smart by management to drop that AH as there is less volume/liquidity for people to panic. Smart investors understood what was happening and bought up those shares. That's why we are back to .77. I'll be buying more shares tomorrow.
$ICU wow looks promising bought in at .82 with 500 shares 📈 “Regardless of its source, uncontrolled hyperinflammation can lead to vital organ damage and even death. Our SCD therapy works to selectively target the most highly activated cells responsible for inflammation to bring activated cells into a reparative state. This can stop the potential damage of over-activated cells and potentially reverse the damage they cause.” What ya think of this one ? Input
This is an uneducated take. Bag holders implies unwarranted price movement to the upside, followed by early loaders selling their shares to new investors. You clearly don't understand the value of going from pre-revenue to revenue as a medtech company. You clearly don't understand the significance of FDA approval on share price or market cap or long term projections. You're view is severely short-sighted. SCD-PED approval, SCD-PED commercial launch, SCD Adult trial results, SCD Adult approval, SCD-Adult commercial launch all before Q2 2025. This doesn't include any of the other indications. You're lack of effort isn't even worth the downvote. Enjoy the sidelines.
You can if you want. It will likely move in the same direction. My problem with Nuwellis long term, is that the agreement is only for the SCD-PED... which means that they don't have the agreement for the adult version. This is the MUCH larger market. Also, if there is any sort of buyout/bigger company that swoops in.. ICU holds the patent. Nuwellis could get left in the dust. Unlikely, but possible.
Any shares bought now will payout huge on approval, and even more significantly if held through the SCD adult study, approval, and commercial launch.
I could definitely see it. They need $ to continue their adult trials. Offering's aren't a bad thing in this situation, especially if you're holding into 2025+ for the big SCD payoff with adults. That's why I'll probably only hold about 5-10k (50-75% in my ROTH) and enjoy the long term upside that comes with entering that market.
Here is my problem with LMFA... $LMFA, $MIGI, $WULF, $MARA, $RIOT, $SLNH, $BETS (scam), etc. These are all companies doing essentially the exact same thing. Why one over the other? How does one pick? How do all investors come to choose one? There is NO other company doing what $ICU is doing with the SCD. Pretty easy decision for me, but you gotta do what you think is best.
I think the company can become a billion dollar company by the end of 2025 when the adult version of the SCD is approved, and commercial launch in motion. For now, 100 million market cap seems more than reasonable, considering the SPAC merger deal was for $85 million back in Oct 2022. And that was BEFORE they had SCD on the brink of approval.
If people don't instantly cash out, this should climb to $3+. I know I will be holding 5,000-10,000 shares into 2025+ for the adult SCD. That is going to be a MASSIVE market and I don't want to miss out on those long term gains.
I appreciate this. I was fortunate to have bought-in at 53¢ around the time they received their patent a few days ago. I intend to hodl. Before buying, I read relevant published research on SCD treatment of AKI, which is what SeaStar Medical does. Patient safety appears to be good and the mechanism of action is interesting, but I am not a biotech expert. I am also not an investing expert (in fact, this was my very first stock purchase). The stock has performed nicely for me over the last week and I'm glad to see that SeaStar Medical is expanding their staff and FDA approval appears to be on track. References (same as those cited on SeaStar Medical's site): 1. Includes the interesting story of how this therapeutic technology was discovered. 2. Is a safety study and appears to be very favorable. 1. Goldstein SL, Askenazi DJ, Basu RK, et al. Use of the Selective Cytopheretic Device in Critically Ill Children. Kidney International Reports. 2020. https://doi.org/10.1016/j.ekir.2020.12.010 2. Tumlin JA, Galphin CM, Tolwani AJ, et al. A multi-center, randomized, controlled, pivotal study to assess the safety and efficacy of a selective cytopheretic device in patients with acute kidney injury. PLoS One. 2015;10(8):e0132482. PMID: 26244978. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132482
As someone from the industry, I can tell you SeaStar Medical is the real deal. Whether Reddit is involved or not, whether it is heavily shorted or not, nothing is going to hold the SCD from ultimately going to market and disrupting the standard of care for patients in an inflammatory state. This is a currently unmet clinical need and SeaStar Medical has truthfully, stumbled upon this clinical solution. It is so very impressive and beautifully simple. The company's priority indications are AKI related, which is a billion dollar market. They have other clear indications that are also high-value markets, see billion dollar markets again. This technology is going to make whoever owns it and takes it to market, billions of dollars in my opinion. Reddit just happens to be early on this right now. This will all change very soon imo. The masses, and most of industry to my surprise, are naive to all of this for the most part. The FDA however is working closely with the company and they funded $1.6M to start the HDE Approval process. That FDA support is very important. We are now just about to see the approval issued. It has taken a long time to get to this point for the company, but it is also ridiculously early in their success story if that is possible. Hope OP has a great personal success with this ICU investment.
we need catalyst like, the news of SCD for adult is having positive progression
Avg cost of device is $10K-20K and already known. Going after Peds AKI market first, already known to top peds hospitals and clinicians already have experience with SCD use per SeaStar. They are targeting the top 50 peds hospital first for immediate traction after commercialization. I believe a realistic target for them with this device is 50% of the 4000 ped AKI cases annually in the US. Traction, uptake and adoption will happening at an accelerated rate with this device - make no mistake about it though, that is very rare, It is an unmet clinical need and physicians will jumps on it when they have positive clinical data to reference - which they do. So with that, you can make some educated guesses to what the total revenues could be. I always personally draw conservative estimates and then calculate blue sky upside - but I base my forecast and evaluations on the conservative side, essentially always allowing for overachieving of the estimate. Without even getting into the adult AKI patient population, this company will be profitable with millions of dollars in revenue by the end of 2024 is my guess. I also think they are likely acquired before the end of the year. They are going after a billion dollar market with a disruptive technology that is already shown to be backed by the FDA. SCD isn't going anywhere after approval and it will affect the dialysis numbers in the US. This will have a negative effect on dialysis revenues and I think one of the major dialysis companies will secure this new device and the emerging market which will be huge,
we need the pricing of the SCD and projected the possible sales for both kid and adult version
CRISPR Tx quietly getting several approvals for world first gene editing treatment for SC Disease. Current addressable sits at over 30k patients. SCD treatment costs 2.1 million. Sounds high but that is less than half of the lifetime costs for chronic care for these victims. Insurance companies already signing up to pay for the treatment. You do the math and DD before the rest of the retail investors do and pump this.
Today's PR was about enrollment in adult clinical trials. They chose to include the blurb about pediatric approval but that timeline has been previously disclosed and wasn't news today. As for the price drop on the news my first guess is that clinical trial enrollment means more cash being spent, something they are pretty low on until/unless the SCD gets approved and commercialized.
actual substance? what about the approved sickle cell crispr therapy that has a pt population of over 20,000 currently and that only includes severe SCD. or check out the cd19 car-ts that are gene edited for higher proliferation, protection, immune evasion, and durability. or in vivo editing of genetic risk factors for high cholesterol and triglycerides - CRSP phase 1 trials in non human primates have shown 90% reduction in serum ldl for 12 months after one infusion.
nobody at all has been talking about biotech, there’s a massive paradigm shift occurring right this second and will change the way we look at medicine in the next 10-20 years as more therapies get approved. gene editing has massive breakthrough disruptive potential, not just CRISPR/Cas9 but also base and prime editing as well. also, the field of multiomics is unlocking so much knowledge that accelerates the advancement of treatments. especially when in vivo gene editing becomes a reality and conditioning/cell transplants are not needed, we’re looking at functional, one time cures. CRSP has the first approved ex vivo CRISPR therapy for SCD/B-Thal, EDIT owns the patent rights for CRISPR human editing, BEAM is working on base editing, NTLA is working on in vivo for SCD currently. most of these companies are tackling hemoglobinopathies bc research has shown CRISPR can cure these diseases. most of these companies currently sit at anywhere from 1-5 billion market cap rn. compare that to a big pharmaceutical like Eli Lilly with a $500 billion market cap.. ¯\_(ツ)_/¯
Hodling $ICU, their 8K today confirms a date of 3/13/24 for the delisting hearing. If things stick to the previously advertised timeline that should be well after the SCD approval decision.
BLUE baby!! Kick these shorts in the nuts for shorting the first gene editing therapy that’s curing SCD
Crisper Tx got approval for SCD the same day and it’s a superior compound.
CRSP is the play for next week. FDA approval looks likely for severe SCD cases on Friday and I think pumps the stock into the 80-85 range even without considering the short squeeze potential. 100+ is certainly a possibility if it does squeeze. This peaked at over 200 back in 2021 with a much less promising financial outlook, so there’s definitely room to run
Try hodling LICY when you bought it higher than could be discussed on this sub! That one was a loooong term play from the beginning so I'm not too worried, but still ICU is pretty mellow in comparison. Anyways, I'm not too surprised on the recent pricing with ICU. Their finances are garbage until/unless the SCD achieves commercialization and they've diluted since the last news, also heavily shorted. I see longer term potential in the stock but it isn't pretty in the meantime.
Who said what about CRSP? They had a very positive Adcomm on 10/31, had their SCD ex-cel treatment approved in the U.K. by the MHRA about a week later (which basically guarantees approval from the FDA on the PDUFA date in a few weeks on 12/8).
They have an approvable letter, which applies to minor changes in how they market it (the SCD) and a plan to study it after its release. From what I have read, they already have the device ready to sell and are just awaiting the final approval, which hopefully comes soon enough for them to meet their goal of commercialization by the end of 2023 or Q1 2024.
You missed out, yesterday was the AdCom for CRSP ex-vivo treatment for SCD. The PDUFA is 12/8.
Sorry for the delay- I’m on a strand of 12s rn. I don’t think that SCD being less costly will impact profitability/earnings. Major medical centers are able to profit by implementing new technologies such as these (I’m no expert on how they do this, but I know that it does increase their status in a way that brings in more earnings). Doctors make the call to use this device, I have never seen a time where we had to get admin/financial approval first (especially in life or death scenarios). If an option is available and it could save someone’s life, then you better believe it will tried. Also, SCDs are designed to be integrated into a machine that we already use often in the icu called CRRT. We use this in hemodynamically unstable patients, many of which have multi-system organ failure or sepsis. It acts as extracorporeal kidneys so that the blood can still be filtered/cleaned (since the kidneys can no longer do so in cases such as these). It also has many applications beyond this. SCDs are intended to easily integrate into the CRRT system. Because hospitals have invested in the cost of having CRRT machines, I see no issues with SCDs being quickly adopted and used on a large scale. Even if it could be considered pocket change to an individual hospital, many hospitals combined means very large profits for this company.
I'm a holder, but I don't see ICU becoming profitable soon. Where are you getting that information? Their own roadmap shows pediatric SCD approval in H1-2024 and for adults in H1-2025. This is long-term play.
ICU (SeaStar Medical) right now AH and again in PM. Shorts got caught with company cancelling their offering and FDA about to finalize their HDE Approval for SCD device. Received their 3rd FDA Breakthrough device just last week. Company is looking great short-term and long-term. Squeeze probably any time now.
ICU because I believe that hyperinflammation is central to so many medical issues, from cancer to aging - this is a life-saving device. Their SCD device has limitless applications...
$ICU long hold because I believe that hyperinflammation is so central to so many issues, from cancer to aging. Their SCD device is organ-agnostic, condition-agnostic and thus has limitless applications...
They're not getting full approval. From investor relations: "Thank you for your interest in SeaStar Medical. The company is expecting an APPROVABLE LETTER by the end of October. The company has been told by the FDA that the SCD-PED is approvable, and SeaStar Medical will receive an APPROVABLE LETTER, which is a normal course in a device approval. The APPROVABLE LETTER will outline the condition that need to be met for APPROVAL. The fact that an APPROVABLE LETTER is being issued is a major, major step in the full APPROVAL process."
I was looking around for ICU things last night and found this video of how the SCD mechanism works: [https://youtu.be/6jrCjJkdzZo?si=XZkHxVxkacriXOWk](https://youtu.be/6jrCjJkdzZo?si=XZkHxVxkacriXOWk)
$BLUE is the play boys. Could be approved for SCD treatment. Very bullish and under discovered still. Good luck
SCD is Sickle Cell Disease, not a ticker. Lol.
Hey /u/MidWestStock - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: SCD. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
Tell her if she truly loves you then she will forgive you! Life a bitch win some loose some! I’m down $300k 70% YTD but restructured my portfolio shifted all into BLUE blue bird bio. If it runs up to half of what it used to be I’ll be over a mill! Better be lucky then good! Time will tell but BLUE looks promising with FDA approvals and SCD in q1 2023! Might be life changer!
First of all I'm biased for Bluebird Bio (bbb) since I did contact work for them on their SCD program shortly after the company split. My experience is that there is a lot of very talented ppl in the organization from other parts of big pharma who decided to stay with bbb because they want to bring the treatment to the finish line and help the patient community. They'll stay even with bigger and better offers from more 'secure' organizations. What you don't hear is that the company is treating CALD/ALD patients for free by opening clinical trials for single patients so that the kids can get treatment right away since timing is critical. [https://www.youtube.com/watch?v=FPCA9puWmDM](https://www.youtube.com/watch?v=FPCA9puWmDM) All these folks could make $$$$ outside of the company but they want to cure young kids who would get a death sentence w/o bluebird's genetic cure (ALD/CALD). Its a CURE, not a treatment!!! The first two in the pipeline have 100% advisory committee approval and first one already approved (beta thalassemia). The clinical data is absolutely amazing for everything I was able to see. If you're interested they went over all the data in detail in the two 8hr advisory committee meetings. I suggest listening to the parents speak about the disease and treatments at time (3:24:00) on day 1. [https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-june-9-10-2022-meeting-announcement-06092022](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-june-9-10-2022-meeting-announcement-06092022) bbb hasn't made good business decisions in the past especially with Nick as CEO (I've met him. He's a really good guy in person but a bit crazy and not grounded in reality...also the guy you want to party with cause he's fun as shit ). The new guy, Andrew, is all business and the one to make tough choices and bring the treatment to market. But what really F'ing mad about it the fuckers who short this company and want to fuck the opportunity to LITERALLY SAVE KIDS because these greedy ass hats don't give a shit about anything. FUCK SHORTS who don't do a fucking thing in life other than wreck someone else's hard work. If you want to short something, stick to finance or crypto or anything else. Anyways, after working for them for a month I bought 1000 shares @$6ish because I believe in the cause even if it went bust. I don't know why ppl got onboard with BBBY or any other stock but if you're looking to actually support a company with a lifechanging product and fuck institutional shorts at the same time, here you go. I get off my soapbox and go fuck myself now.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: SCD. Message /u/zjz if they're above 500 million-ish market cap and not related to crypto/pennies/OTC.
Yeah that's still in phase 1. [Here](https://www.biospace.com/article/crispr-and-viacyte-announce-phase-i-clinical-trial-for-type-1-diabetes/) talks a bit about how they're going about it. Not needing chemo like many other gene editing treatments is a game changer. It's still very early though. The TDT and SCD treatments are in phase 3. [This](http://www.crisprtx.com/about-us/press-releases-and-presentations/vertex-and-crispr-therapeutics-present-new-data-on-more-patients-with-longer-follow-up-treated-with-exagamglogene-autotemcel-exa-cel-at-the-2022-european-hematology-association-eha-congress) is their press release that talks about the outcomes. Looks good as far as I can tell.
I am a bot. You submitted a picture of a banned ticker, SCD. The market cap of SCD is **234700600** This check will fire if you included unnecessary pictures that have bad keywords/phrases. Repost with the useless pictures omitted if you did that.
There is no way I have that kind of power - Thank YOU for the encouragement though!! - Its Just a Good Buy and now you have the opportunity - people said the same think when I suggested RDBX at 1.05 and $REV at 1.08 check my post I use a controversial and sometime questionable methodology - SCD for research and STS for strategy
I always say - lets wait and see - they laughed at me on $RDBX at $1.59 I research the market differently and aggressively for profits and turning equity into income - SCD is a research philosophy which helps me see the pattern, The Price the Historical Data as a MOVING point of where the stock will go based on where it has been along with Social Sentiment
you are right - so far so good - I read he uses SCD for research something he wrote back in 2006
Not Heavy at all - all I talked about has come to past - SCD and STS works
here is the ride I use SCD and it works - Never Follow me, Follow The Results!!
Trading stocks will never be the same - We No Longer Look at the Fundamentals, the earnings, options, analyst research... Social Sentiment is a key indicator... with that being said I utilize SCD in all I do
these are end-result real-time predications based on SCD - The Paradigm shift has arrived
It's not a random number its based on a Research strategy I utilize to help price stocks, based on History, Social Sentiment, Current Events, Catalyst and historical price Patterns - SCD "Systematic Concept Duplication... so after looking at the stock before the $AMC news I seen $15 over two years - so it was going to be a In/out play for me - after the news.. I considered $AMC, its Influence and Then Eric Sprott and His influence.... the number was Higher, on 24 Months - so what I did was decrease the time to the next 3 Quarters... $40-$50 dollar rang with experience Several SPIKES
I am still bullish and know what I see - my controversial methodology for trading and buying stocks, SCD works 80% of the time and I am solid on what I see - in at $16 2/22... up ever since .. small set back - lets talk again on the other side of $25
wow....you are challenging me... If you want a Good way to go and a good long-term investment - $RDBX - but since you asked on their Mobile app Once the algorithm picks up on the increased relevancy driven by their ASA campaign, I saw a positive impact on $RDBX organic ranking within the app store and also in Google play store – each of the app’s relevancy for specific keywords gains traction, Apple's algorithm allowed for me to see a repeated pattern of impressions shares in relation to actual consumer engagement through actual consumer taps. I look for repeated patterns, on all platforms before making an actual execution on any trade and then I share the results of my DD SCD - Systematic Concept Duplication is my written rule for trading and buying stocks